estradiol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
estrogens 1057 50-28-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • estradiol
  • 17Beta-Estradiol
  • 17Beta-Oestradiol
  • Beta-Estradiol
  • estradiol hemihydrate
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
  • Molecular weight: 272.39
  • Formula: C18H24O2
  • CLOGP: 3.78
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS: -4.11
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 mg N
2 mg O
1 mg P
0.30 mg P
5 mg R
50 mcg TD
1 mg TD
1.53 mg TD
25 mcg V
7.50 mcg V

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.09 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 1.84 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.20 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 23, 1975 FDA BRISTOL MYERS SQUIBB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product adhesion issue 4771.23 9.90 1222 87967 4275 53255602
Hot flush 1151.81 9.90 807 88382 46353 53213524
Application site rash 893.50 9.90 283 88906 2413 53257464
Application site erythema 570.24 9.90 240 88949 4851 53255026
Application site pruritus 530.46 9.90 215 88974 3934 53255943
Product quality issue 501.48 9.90 448 88741 36575 53223302
Product physical issue 478.03 9.90 214 88975 5048 53254829
Application site irritation 442.10 9.90 152 89037 1712 53258165
Meningioma 348.84 9.90 155 89034 3589 53256288
Wrong technique in product usage process 314.30 9.90 442 88747 59590 53200287
Vulvovaginal discomfort 299.79 9.90 121 89068 2188 53257689
Application site reaction 255.10 9.90 81 89108 696 53259181
Menopausal symptoms 216.11 9.90 93 89096 1988 53257889
Death 208.41 9.90 175 89014 357057 52902820
Vulvovaginal pain 206.56 9.90 94 89095 2305 53257572
Vaginal haemorrhage 179.60 9.90 223 88966 26618 53233259
Vulvovaginal burning sensation 174.55 9.90 76 89113 1673 53258204
Application site pain 173.07 9.90 100 89089 4083 53255794
Pneumonia viral 171.69 9.90 121 89068 6991 53252886
Breast tenderness 162.18 9.90 79 89110 2267 53257610
Toxicity to various agents 158.21 9.90 85 89104 219513 53040364
Device adhesion issue 157.89 9.90 90 89099 3580 53256297
Pemphigus 151.33 9.90 5 89184 104026 53155851
Blood oestrogen decreased 145.60 9.90 42 89147 250 53259627
Vulvovaginal dryness 141.91 9.90 73 89116 2359 53257518
Vaginal discharge 132.23 9.90 95 89094 5658 53254219
Application site vesicles 130.08 9.90 59 89130 1435 53258442
Postmenopausal haemorrhage 128.63 9.90 66 89123 2121 53257756
Application site urticaria 128.10 9.90 38 89151 253 53259624
Soft tissue disorder 127.44 9.90 83 89106 4207 53255670
Device material issue 122.98 9.90 34 89155 169 53259708
Completed suicide 121.10 9.90 40 89149 138161 53121716
Fibromyalgia 117.24 9.90 240 88949 43835 53216042
Product complaint 116.20 9.90 122 89067 12135 53247742
Colitis microscopic 114.57 9.90 95 89094 6999 53252878
Migraine 111.07 9.90 341 88848 80076 53179801
Application site burn 109.92 9.90 45 89144 845 53259032
Incorrect dose administered by product 109.21 9.90 30 89159 145 53259732
Ovarian hyperstimulation syndrome 108.14 9.90 70 89119 3511 53256366
Hand deformity 108.13 9.90 9 89180 84840 53175037
Product substitution issue 103.21 9.90 130 89059 15736 53244141
Glossodynia 101.11 9.90 22 89167 100269 53159608
Feeling abnormal 100.99 9.90 471 88718 134830 53125047
Acute kidney injury 96.52 9.90 173 89016 253695 53006182
Hormone level abnormal 95.36 9.90 56 89133 2357 53257520
Skin reaction 91.34 9.90 107 89082 12016 53247861
Night sweats 89.07 9.90 187 89002 34760 53225117
Febrile neutropenia 87.41 9.90 33 89156 104903 53154974
Neutropenia 85.45 9.90 84 89105 159101 53100776
Anti-cyclic citrullinated peptide antibody positive 82.24 9.90 3 89186 57169 53202708
Schizoaffective disorder 82.05 9.90 49 89140 2128 53257749
Skin irritation 80.45 9.90 84 89105 8300 53251577
Product dose omission issue 80.31 9.90 572 88617 191048 53068829
Systemic lupus erythematosus 79.87 9.90 56 89133 125358 53134519
Hysterectomy 77.23 9.90 83 89106 8478 53251399
Maternal exposure during pregnancy 75.88 9.90 89 89100 155550 53104327
Pancytopenia 71.81 9.90 31 89158 90897 53168980
Wound 71.06 9.90 32 89157 91525 53168352
Glaucoma 70.04 9.90 112 89077 16891 53242986
Intermenstrual bleeding 69.27 9.90 79 89110 8619 53251258
Vaginal infection 69.06 9.90 69 89120 6472 53253405
Vaginal odour 68.85 9.90 27 89162 451 53259426
Drug ineffective 68.75 9.90 1818 87371 815427 52444450
Headache 68.15 9.90 1267 87922 535554 52724323
Thrombocytopenia 67.98 9.90 79 89110 138648 53121229
Application site hypersensitivity 67.42 9.90 22 89167 208 53259669
Exposure during pregnancy 66.86 9.90 66 89123 124794 53135083
Vulvovaginal pruritus 64.30 9.90 45 89144 2570 53257307
Intentional overdose 61.44 9.90 18 89171 67187 53192690
Depression 61.43 9.90 519 88670 182533 53077344
Hyperkalaemia 60.95 9.90 9 89180 54247 53205630
Thyroid disorder 60.01 9.90 92 89097 13381 53246496
Oestrogen receptor assay positive 59.55 9.90 24 89165 432 53259445
Insomnia 59.43 9.90 524 88665 186548 53073329
Arthritis 59.38 9.90 296 88893 87002 53172875
Hypotension 58.95 9.90 222 88967 253854 53006023
Cardiac arrest 58.09 9.90 43 89146 93624 53166253
General physical health deterioration 57.72 9.90 98 89091 146844 53113033
Pyrexia 57.66 9.90 416 88773 402777 52857100
Blood cholesterol increased 57.35 9.90 207 88982 52782 53207095
Incorrect dose administered by device 56.33 9.90 47 89142 3492 53256385
Sepsis 56.29 9.90 99 89090 146330 53113547
Pericarditis 55.76 9.90 19 89170 64387 53195490
Rheumatoid arthritis 55.53 9.90 304 88885 314227 52945650
Cardiac failure 55.08 9.90 38 89151 85806 53174071
Contraindicated product administered 54.62 9.90 89 89100 135540 53124337
Diverticulitis 54.31 9.90 157 89032 35644 53224233
Herpes zoster 53.94 9.90 256 88933 73763 53186114
Salpingo-oophorectomy unilateral 53.90 9.90 25 89164 641 53259236
Application site scar 53.65 9.90 19 89170 235 53259642
Product shape issue 53.44 9.90 17 89172 147 53259730
Breast pain 52.84 9.90 67 89122 8162 53251715
Hyperhidrosis 52.82 9.90 309 88880 96484 53163393
Multiple organ dysfunction syndrome 52.59 9.90 14 89175 55663 53204214
Uterine haemorrhage 52.50 9.90 47 89142 3840 53256037
Product packaging issue 52.31 9.90 29 89160 1092 53258785
Incorrect dose administered 51.55 9.90 195 88994 50850 53209027
Arthropathy 51.38 9.90 99 89090 141354 53118523
Wrong technique in device usage process 51.10 9.90 39 89150 2548 53257329
Rheumatoid factor positive 50.78 9.90 5 89184 41193 53218684
Liver function test abnormal 50.51 9.90 186 89003 47885 53211992
Blood oestrogen increased 50.29 9.90 15 89174 102 53259775
Vaginal erosion 50.05 9.90 12 89177 29 53259848
Product availability issue 50.01 9.90 35 89154 1999 53257878
Application site erosion 49.63 9.90 17 89172 189 53259688
Respiratory failure 49.48 9.90 57 89132 100455 53159422
Drug abuse 49.15 9.90 24 89165 65502 53194375
No adverse event 49.14 9.90 161 89028 39104 53220773
Sinusitis fungal 48.91 9.90 30 89159 1368 53258509
Progesterone receptor assay positive 48.36 9.90 19 89170 319 53259558
Platelet count decreased 48.31 9.90 66 89123 108033 53151844
Cardio-respiratory arrest 48.05 9.90 19 89170 58739 53201138
Application site swelling 47.87 9.90 22 89167 552 53259325
Breast cancer 46.94 9.90 185 89004 49173 53210704
Disease progression 46.80 9.90 61 89128 101859 53158018
Bronchitis 46.80 9.90 334 88855 111565 53148312
Fungal infection 46.61 9.90 139 89050 32107 53227770
Mucosal inflammation 46.02 9.90 8 89181 42776 53217101
Breast enlargement 45.13 9.90 30 89159 1574 53258303
Oral pain 44.94 9.90 122 89067 26715 53233162
Breast cancer in situ 44.77 9.90 29 89160 1456 53258421
Butterfly rash 44.56 9.90 26 89163 1081 53258796
Application site discolouration 43.42 9.90 23 89166 790 53259087
Renal failure 42.06 9.90 84 89105 118368 53141509
Application site inflammation 41.85 9.90 18 89171 384 53259493
Duodenal ulcer perforation 41.51 9.90 5 89184 35178 53224699
Application site dermatitis 40.93 9.90 15 89174 206 53259671
Infusion related reaction 40.35 9.90 130 89059 155827 53104050
Sputum increased 40.33 9.90 32 89157 2214 53257663
Embolism venous 39.99 9.90 36 89153 2963 53256914
Malignant neoplasm progression 39.23 9.90 37 89152 71504 53188373
Product odour abnormal 38.74 9.90 25 89164 1247 53258630
Overdose 38.60 9.90 76 89113 107660 53152217
Helicobacter infection 38.50 9.90 9 89180 39060 53220817
Septic shock 38.02 9.90 29 89160 62200 53197677
Lactic acidosis 37.88 9.90 8 89181 37245 53222632
Respiratory symptom 37.71 9.90 33 89156 2616 53257261
Product size issue 37.23 9.90 17 89172 420 53259457
Vulvovaginal mycotic infection 37.06 9.90 43 89146 4779 53255098
Bladder prolapse 36.74 9.90 29 89160 1991 53257886
Uterine leiomyoma 36.72 9.90 58 89131 8654 53251223
Nasal polyps 36.32 9.90 34 89155 2942 53256935
Oestradiol increased 36.24 9.90 11 89178 80 53259797
Oestradiol decreased 36.13 9.90 9 89180 27 53259850
Renal impairment 36.10 9.90 52 89137 83266 53176611
Mood swings 36.05 9.90 86 89103 17400 53242477
Product packaging quantity issue 36.00 9.90 24 89165 1265 53258612
Muscle spasms 36.00 9.90 364 88825 134431 53125446
Blood creatinine increased 35.41 9.90 52 89137 82610 53177267
Fibrocystic breast disease 35.11 9.90 23 89166 1177 53258700
Application site exfoliation 34.54 9.90 15 89174 328 53259549
Haemoglobin decreased 34.45 9.90 116 89073 137191 53122686
Poor quality product administered 34.22 9.90 34 89155 3167 53256710
Dermatitis contact 34.20 9.90 57 89132 8895 53250982
Placenta accreta 33.95 9.90 13 89176 203 53259674
Breast cancer female 33.94 9.90 49 89140 6755 53253122
Hypothalamo-pituitary disorder 33.93 9.90 19 89170 730 53259147
Nipple pain 33.85 9.90 14 89175 270 53259607
Device use issue 33.52 9.90 27 89162 1909 53257968
Application site dryness 32.86 9.90 12 89177 163 53259714
Menopause 32.48 9.90 29 89160 2361 53257516
Endometrial cancer 32.25 9.90 32 89157 2976 53256901
Pneumonia 31.86 9.90 484 88705 406685 52853192
Hypoglycaemia 31.80 9.90 31 89158 58982 53200895
Anxiety 31.66 9.90 483 88706 196221 53063656
Therapeutic response unexpected 31.45 9.90 81 89108 17189 53242688
Bradycardia 31.12 9.90 44 89145 71012 53188865
Hyponatraemia 30.61 9.90 87 89102 108520 53151357
Endometrial hyperplasia 30.41 9.90 18 89171 769 53259108
Chronic sinusitis 29.93 9.90 43 89146 5902 53253975
Sleep disorder due to general medical condition, insomnia type 29.89 9.90 3 89186 24346 53235531
Anaemia 29.87 9.90 307 88882 276411 52983466
Product prescribing issue 29.75 9.90 21 89168 1216 53258661
Pleural effusion 29.60 9.90 65 89124 88514 53171363
Bone marrow failure 29.55 9.90 7 89182 30108 53229769
Endometrial cancer stage I 29.47 9.90 12 89177 222 53259655
Metabolic acidosis 29.43 9.90 17 89172 42225 53217652
Gastrointestinal haemorrhage 29.35 9.90 56 89133 80274 53179603
Osteopenia 29.30 9.90 82 89107 18273 53241604
Abdominal distension 29.29 9.90 231 88958 79559 53180318
Interstitial lung disease 29.11 9.90 33 89156 58589 53201288
Vitamin D decreased 28.68 9.90 52 89137 8677 53251200
Colitis ischaemic 28.65 9.90 59 89130 10815 53249062
Hepatic function abnormal 28.46 9.90 13 89176 36886 53222991
Ophthalmic vein thrombosis 28.36 9.90 10 89179 122 53259755
Endometrial stromal sarcoma 28.35 9.90 7 89182 20 53259857
Application site ulcer 28.28 9.90 10 89179 123 53259754
Vulvovaginal injury 28.01 9.90 14 89175 425 53259452
Lower respiratory tract infection 27.82 9.90 70 89119 90911 53168966
Female genital tract fistula 27.59 9.90 34 89155 4024 53255853
Suicide attempt 27.54 9.90 34 89155 58134 53201743
Cholestasis 27.51 9.90 7 89182 28688 53231189
Pseudoprecocious puberty 26.98 9.90 5 89184 0 53259877
Breast discomfort 26.94 9.90 14 89175 462 53259415
Vomiting 26.80 9.90 630 88559 496509 52763368
Hypokalaemia 26.70 9.90 78 89111 96439 53163438
Palpitations 26.65 9.90 275 88914 102073 53157804
Tinnitus 26.32 9.90 111 89078 30408 53229469
Therapeutic product effect increased 26.26 9.90 19 89170 1144 53258733
Diaphragmatic rupture 26.23 9.90 11 89178 220 53259657
Vision blurred 26.22 9.90 238 88951 85366 53174511
Rectal prolapse 26.02 9.90 23 89166 1848 53258029
Dyspareunia 25.96 9.90 26 89163 2445 53257432
Hypoxia 25.89 9.90 33 89156 55647 53204230
Treatment failure 25.51 9.90 119 89070 128284 53131593
Irritability 25.48 9.90 111 89078 30842 53229035
Dermal absorption impaired 25.17 9.90 6 89183 14 53259863
Influenza like illness 25.04 9.90 181 89008 60678 53199199
Atrial fibrillation 24.92 9.90 99 89090 111553 53148324
Dehydration 24.85 9.90 172 89017 168238 53091639
Diastolic dysfunction 24.76 9.90 39 89150 5805 53254072
Tachycardia 24.76 9.90 95 89094 108117 53151760
Dyspnoea 24.57 9.90 770 88419 585462 52674415
Spinal operation 24.54 9.90 41 89148 6410 53253467
Delirium 24.43 9.90 20 89169 41409 53218468
White blood cell count decreased 24.35 9.90 116 89073 124359 53135518
Carpal tunnel syndrome 24.18 9.90 75 89114 17692 53242185
Periodontal disease 24.17 9.90 21 89168 1649 53258228
Endometrial hypertrophy 24.08 9.90 11 89178 272 53259605
Libido decreased 23.97 9.90 26 89163 2683 53257194
Application site discomfort 23.96 9.90 12 89177 366 53259511
Altered state of consciousness 23.92 9.90 6 89183 24830 53235047
Skin burning sensation 23.82 9.90 57 89132 11553 53248324
International normalised ratio increased 23.59 9.90 27 89162 47734 53212143
Paraesthesia 23.22 9.90 320 88869 127195 53132682
Folliculitis 23.19 9.90 12 89177 31697 53228180
Fall 23.16 9.90 441 88748 357999 52901878
Neutrophil count decreased 22.93 9.90 29 89160 49069 53210808
Device breakage 22.90 9.90 53 89136 10514 53249363
Pregnancy 22.85 9.90 12 89177 31429 53228448
Abdominal discomfort 22.72 9.90 248 88941 220814 53039063
Application site discharge 22.54 9.90 9 89180 158 53259719
Eczema 22.47 9.90 90 89099 24092 53235785
Meniscus injury 22.32 9.90 40 89149 6615 53253262
Vessel puncture site bruise 22.10 9.90 11 89178 331 53259546
Vulvovaginal erythema 21.72 9.90 10 89179 252 53259625
Shock 21.51 9.90 6 89183 23133 53236744
Decreased appetite 21.37 9.90 243 88946 214731 53045146
Breast calcifications 21.31 9.90 17 89172 1185 53258692
Injection site inflammation 21.28 9.90 27 89162 3291 53256586
Normal tension glaucoma 21.19 9.90 7 89182 69 53259808
Spinal stenosis 21.16 9.90 62 89127 14179 53245698
Erythema of eyelid 20.99 9.90 21 89168 1973 53257904
Product colour issue 20.98 9.90 14 89175 739 53259138
Coma 20.92 9.90 45 89144 61738 53198139
Cardiac failure congestive 20.85 9.90 82 89107 92675 53167202
Stress 20.80 9.90 165 89024 56919 53202958
Breast mass 20.65 9.90 39 89150 6712 53253165
Heavy menstrual bleeding 20.62 9.90 70 89119 17306 53242571
Sopor 20.49 9.90 5 89184 21079 53238798
Pericardial effusion 20.44 9.90 10 89179 27268 53232609
Intestinal polyp 20.42 9.90 17 89172 1259 53258618
Drug reaction with eosinophilia and systemic symptoms 20.40 9.90 15 89174 32785 53227092
Respiratory distress 20.36 9.90 16 89173 33811 53226066
Photosensitivity reaction 20.35 9.90 60 89129 13768 53246109
Memory impairment 20.32 9.90 224 88965 84533 53175344
Histamine intolerance 20.22 9.90 6 89183 40 53259837
Diverticulum 20.17 9.90 54 89135 11725 53248152
Pituitary tumour 20.16 9.90 15 89174 943 53258934
Atypical haemolytic uraemic syndrome 19.93 9.90 12 89177 529 53259348
Change of bowel habit 19.73 9.90 20 89169 1908 53257969
Feeling hot 19.73 9.90 128 89061 41416 53218461
Sleep apnoea syndrome 19.71 9.90 91 89098 25911 53233966
Emotional disorder 19.62 9.90 57 89132 12973 53246904
Cystocele 19.30 9.90 16 89173 1178 53258699
Porphyria non-acute 19.27 9.90 10 89179 329 53259548
Ventricular dyskinesia 19.26 9.90 8 89181 156 53259721
Bone density abnormal 19.13 9.90 25 89164 3137 53256740
Pre-existing condition improved 19.13 9.90 42 89147 8047 53251830
Oxygen saturation decreased 19.11 9.90 65 89124 76660 53183217
Sinus rhythm 19.11 9.90 13 89176 709 53259168
Vaginal disorder 19.07 9.90 13 89176 711 53259166
Corticosteroid binding globulin increased 18.82 9.90 4 89185 4 53259873
Lymphogranuloma venereum 18.82 9.90 4 89185 4 53259873
Respiratory arrest 18.79 9.90 17 89172 33523 53226354
Confusional state 18.73 9.90 221 88968 194000 53065877
Lung disorder 18.72 9.90 32 89157 47847 53212030
Productive cough 18.65 9.90 42 89147 56687 53203190
Breast disorder 18.62 9.90 21 89168 2263 53257614
Acute respiratory failure 18.54 9.90 15 89174 31243 53228634
Incorrect product administration duration 18.49 9.90 49 89140 10575 53249302
Uterine polyp 18.22 9.90 19 89170 1874 53258003
Loss of personal independence in daily activities 18.18 9.90 58 89131 69757 53190120
Poor quality sleep 18.17 9.90 67 89122 17256 53242621
Device expulsion 18.07 9.90 14 89175 29799 53230078
Tricuspid valve incompetence 17.98 9.90 59 89130 14337 53245540
Application site laceration 17.93 9.90 4 89185 6 53259871
Rectocele 17.89 9.90 14 89175 949 53258928
Product administered at inappropriate site 17.88 9.90 22 89167 2600 53257277
Pneumocystis jirovecii pneumonia 17.75 9.90 3 89186 16375 53243502
Osteoarthritis 17.69 9.90 188 89001 70298 53189579
Palmar-plantar erythrodysaesthesia syndrome 17.64 9.90 7 89182 21599 53238278
Spider naevus 17.32 9.90 7 89182 127 53259750
Bacterial vulvovaginitis 17.21 9.90 12 89177 681 53259196
Amnesia 17.10 9.90 132 89057 45156 53214721
Drug resistance 17.08 9.90 6 89183 19956 53239921
Pelvic infection 17.05 9.90 9 89180 307 53259570
Gastrooesophageal reflux disease 16.94 9.90 212 88977 82451 53177426
Prosopagnosia 16.89 9.90 5 89184 33 53259844
Low density lipoprotein increased 16.89 9.90 34 89155 6132 53253745
Atrophic vulvovaginitis 16.86 9.90 17 89172 1612 53258265
Breast cyst 16.81 9.90 17 89172 1617 53258260
Acute respiratory distress syndrome 16.81 9.90 9 89180 23323 53236554
Periorbital oedema 16.63 9.90 31 89158 5284 53254593
Joint swelling 16.61 9.90 284 88905 234354 53025523
Burning sensation 16.53 9.90 137 89052 47876 53212001
Product taste abnormal 16.50 9.90 19 89170 2094 53257783
Intentional self-injury 16.47 9.90 11 89178 25273 53234604
Peritonitis 16.17 9.90 8 89181 21679 53238198
Condition aggravated 16.12 9.90 376 88813 296758 52963119
Surgery 16.12 9.90 100 89089 31864 53228013
Craniopharyngioma 16.08 9.90 7 89182 154 53259723
Vulvovaginal swelling 16.03 9.90 10 89179 470 53259407
Ovarian atrophy 15.95 9.90 6 89183 89 53259788
Vulvovaginal inflammation 15.80 9.90 11 89178 623 53259254
Hepatotoxicity 15.78 9.90 14 89175 27866 53232011
Abnormal dreams 15.60 9.90 46 89143 10555 53249322
Anosmia 15.58 9.90 27 89162 4348 53255529
Procedural pain 15.50 9.90 57 89132 14660 53245217
Aptyalism 15.44 9.90 10 89179 502 53259375
Therapeutic product effect decreased 15.41 9.90 135 89054 125520 53134357
Product physical consistency issue 15.33 9.90 10 89179 508 53259369
Bone density decreased 15.33 9.90 47 89142 11017 53248860
Procedural anxiety 15.32 9.90 11 89178 654 53259223
Swelling 15.30 9.90 226 88963 190879 53068998
Breast swelling 15.19 9.90 14 89175 1188 53258689
Muscle fatigue 14.99 9.90 19 89170 2314 53257563
Suspected product quality issue 14.90 9.90 7 89182 185 53259692
Breast engorgement 14.89 9.90 6 89183 108 53259769
Crying 14.78 9.90 75 89114 22187 53237690
Neoplasm progression 14.68 9.90 17 89172 29902 53229975
Product outer packaging issue 14.62 9.90 4 89185 19 53259858
Diarrhoea 14.58 9.90 877 88312 624669 52635208
Fluid overload 14.55 9.90 15 89174 27816 53232061
Thyroxine decreased 14.53 9.90 10 89179 556 53259321
Thermal burn 14.51 9.90 29 89160 5204 53254673
Expulsion of medication 14.45 9.90 4 89185 20 53259857
Ultrasound liver abnormal 14.45 9.90 4 89185 20 53259857
Bladder pain 14.39 9.90 16 89173 1697 53258180
Acute hepatic failure 14.35 9.90 5 89184 16715 53243162
Application site infection 14.18 9.90 5 89184 61 53259816
Drug intolerance 14.13 9.90 250 88939 205243 53054634
Withdrawal bleed 14.04 9.90 6 89183 126 53259751
Electrolyte imbalance 14.03 9.90 7 89182 18877 53241000
Encephalopathy 14.03 9.90 25 89164 36783 53223094
Application site pustules 13.70 9.90 4 89185 25 53259852
Trans-sexualism 13.65 9.90 3 89186 4 53259873
Disseminated intravascular coagulation 13.64 9.90 8 89181 19711 53240166
Haematemesis 13.62 9.90 19 89170 30838 53229039
Blood pressure systolic abnormal 13.53 9.90 34 89155 7105 53252772
Emphysema 13.52 9.90 42 89147 9917 53249960
Poor venous access 13.48 9.90 42 89147 9933 53249944
Sinusitis 13.43 9.90 373 88816 168191 53091686
Patient dissatisfaction with treatment 13.43 9.90 5 89184 72 53259805
Periodontitis 13.32 9.90 22 89167 3407 53256470
Psoriasis 13.28 9.90 212 88977 86877 53173000
Oral herpes 13.13 9.90 70 89119 21109 53238768
Mood altered 13.12 9.90 52 89137 13849 53246028
Alanine aminotransferase abnormal 13.07 9.90 23 89166 3750 53256127
Pain in extremity 13.05 9.90 592 88597 284458 52975419
Plasma cell myeloma 13.01 9.90 39 89150 47835 53212042
Blood oestrogen abnormal 12.90 9.90 3 89186 6 53259871
Insulin-like growth factor increased 12.86 9.90 11 89178 846 53259031
Cor pulmonale acute 12.80 9.90 8 89181 377 53259500
Road traffic accident 12.80 9.90 80 89109 25551 53234326
Melaena 12.79 9.90 18 89171 29111 53230766
Tenderness 12.77 9.90 66 89123 19664 53240213
Gastrointestinal disorder 12.74 9.90 93 89096 89911 53169966
Endometrial disorder 12.70 9.90 10 89179 684 53259193
Pulmonary arterial hypertension 12.68 9.90 16 89173 27106 53232771
Therapy non-responder 12.65 9.90 41 89148 49079 53210798
Application site nodule 12.59 9.90 3 89186 7 53259870
Unresponsive to stimuli 12.47 9.90 23 89166 33403 53226474
Pneumonia aspiration 12.45 9.90 24 89165 34277 53225600
Pulmonary oedema 12.39 9.90 47 89142 53676 53206201
Breast hyperplasia 12.38 9.90 7 89182 274 53259603
Intervertebral disc degeneration 12.32 9.90 52 89137 14246 53245631
Drug interaction 12.32 9.90 276 88913 219053 53040824
Device physical property issue 12.27 9.90 15 89174 1760 53258117
Expired product administered 12.22 9.90 29 89160 5847 53254030
Hepatic failure 12.19 9.90 26 89163 35780 53224097
Device defective 12.17 9.90 13 89176 1318 53258559
Hyperglycaemia 12.12 9.90 31 89158 40053 53219824
Head discomfort 12.09 9.90 45 89144 11639 53248238
Sleep disorder 12.07 9.90 151 89038 58719 53201158
Foetal exposure during pregnancy 11.99 9.90 25 89164 34690 53225187
Pulmonary congestion 11.99 9.90 6 89183 16150 53243727
Retinal vein thrombosis 11.98 9.90 8 89181 423 53259454
Ileus 11.96 9.90 5 89184 14950 53244927
Gingival recession 11.94 9.90 13 89176 1347 53258530
Uterine disorder 11.88 9.90 19 89170 2865 53257012
Hypogonadism 11.88 9.90 5 89184 101 53259776
Abnormal uterine bleeding 11.83 9.90 13 89176 1361 53258516
Vitreous floaters 11.83 9.90 28 89161 5637 53254240
Soft tissue swelling 11.79 9.90 11 89178 948 53258929
Application site scab 11.77 9.90 6 89183 190 53259687
Hospitalisation 11.75 9.90 70 89119 70942 53188935
Muscle atrophy 11.71 9.90 30 89159 6344 53253533
Osteoporosis 11.69 9.90 124 89065 46336 53213541
Vaginal prolapse 11.65 9.90 8 89181 443 53259434
Blood pressure abnormal 11.59 9.90 49 89140 13434 53246443
Premature delivery 11.59 9.90 16 89173 26088 53233789
Eosinophilic pleural effusion 11.56 9.90 4 89185 46 53259831
Muscle injury 11.54 9.90 20 89169 29746 53230131
Breast disorder female 11.48 9.90 5 89184 110 53259767
Product residue present 11.48 9.90 23 89166 4133 53255744
Weight increased 11.44 9.90 434 88755 204133 53055744
Benign breast neoplasm 11.41 9.90 12 89177 1195 53258682
Premature menopause 11.37 9.90 10 89179 798 53259079
Underdose 11.27 9.90 68 89121 21454 53238423
Diabetic ketoacidosis 11.27 9.90 10 89179 19905 53239972
Blood corticotrophin increased 11.26 9.90 4 89185 50 53259827
External ear disorder 11.26 9.90 4 89185 50 53259827
Parotid gland enlargement 11.19 9.90 10 89179 815 53259062
Jaundice 11.18 9.90 21 89168 30292 53229585
Rheumatoid nodule 11.17 9.90 3 89186 11861 53248016
Agranulocytosis 11.11 9.90 14 89175 23735 53236142
Breast cancer stage I 11.08 9.90 13 89176 1462 53258415
Hypothermia 11.04 9.90 4 89185 13052 53246825
Product prescribing error 10.96 9.90 71 89118 22960 53236917
Neurotoxicity 10.94 9.90 6 89183 15343 53244534
Hiatus hernia 10.93 9.90 63 89126 19557 53240320
Xanthoma 10.91 9.90 4 89185 55 53259822
Infusion site erythema 10.88 9.90 36 89153 8786 53251091
Stress urinary incontinence 10.83 9.90 16 89173 2251 53257626
Low turnover osteopathy 10.79 9.90 23 89166 4317 53255560
Accidental overdose 10.76 9.90 12 89177 21467 53238410
Red blood cell sedimentation rate increased 10.74 9.90 19 89170 28038 53231839
Product storage error 10.74 9.90 47 89142 13083 53246794
Disturbance in attention 10.73 9.90 96 89093 34287 53225590
Spinal osteoarthritis 10.73 9.90 52 89137 15105 53244772
Blood testosterone decreased 10.72 9.90 4 89185 58 53259819
Carpal tunnel decompression 10.70 9.90 10 89179 864 53259013
Mesenteric haemorrhage 10.59 9.90 4 89185 60 53259817
Inappropriate schedule of product administration 10.57 9.90 180 89009 74698 53185179
Alopecia 10.54 9.90 305 88884 234278 53025599
Musculoskeletal stiffness 10.54 9.90 144 89045 123224 53136653
Blood bilirubin increased 10.52 9.90 28 89161 35702 53224175
Uterine spasm 10.44 9.90 8 89181 526 53259351
Prolapse 10.38 9.90 3 89186 18 53259859
Mammogram abnormal 10.35 9.90 9 89180 707 53259170
Impatience 10.32 9.90 7 89182 380 53259497
Dry mouth 10.25 9.90 148 89041 59402 53200475
Myalgia 10.24 9.90 294 88895 133197 53126680
Mobility decreased 10.23 9.90 80 89109 76191 53183686
Swelling face 10.21 9.90 143 89046 57025 53202852
Stomatitis 10.12 9.90 110 89079 98048 53161829
Seizure 10.07 9.90 154 89035 129355 53130522
Tongue erythema 10.06 9.90 6 89183 260 53259617
Tuberculosis 10.05 9.90 3 89186 11068 53248809
Gingival ulceration 10.04 9.90 10 89179 934 53258943
Premature baby 9.99 9.90 11 89178 19790 53240087
Adnexa uteri pain 9.94 9.90 7 89182 404 53259473
Uterine cancer 9.93 9.90 21 89168 3920 53255957
Labyrinthitis 9.93 9.90 15 89174 2153 53257724
Tooth fracture 9.93 9.90 38 89151 9960 53249917

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Meningioma 101.48 41.07 19 730 1456 32511321
Off label use 58.26 41.07 51 698 306269 32206508
Foetal exposure during pregnancy 58.06 41.07 25 724 41276 32471501
Prolactin-producing pituitary tumour 46.71 41.07 6 743 34 32512743
Hyperprolactinaemia 42.31 41.07 9 740 1309 32511468

Pharmacologic Action:

SourceCodeDescription
ATC G03CA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ESTROGENS
Natural and semisynthetic estrogens, plain
ATC G03AA14 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AA17 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, fixed combinations
ATC G03AB08 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Progestogens and estrogens, sequential preparations
ATC G03CA53 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ESTROGENS
Natural and semisynthetic estrogens, plain
ATC H01CC54 SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
HYPOTHALAMIC HORMONES
Anti-gonadotropin-releasing hormones
FDA CS M0447348 Estradiol Congeners
FDA MoA N0000000100 Estrogen Receptor Agonists
MeSH PA D004967 Estrogens
MeSH PA D006728 Hormones
FDA EPC N0000175825 Estrogen
CHEBI has role CHEBI:50114 oestrogene
CHEBI has role CHEBI:62872 aldehyde oxidase (EC 1.2.3.1) inhibitors
CHEBI has role CHEBI:75771 Mus musculus metabolite
CHEBI has role CHEBI:77746 H. sapiens metabolites
CHEBI has role CHEBI:83056 Daphnia magna metabolites
CHEBI has role CHEBI:176497 anti-aging drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Premenstrual dysphoric disorder indication 596004
Contraception indication 13197004
Female hypogonadism syndrome indication 16041008
Atrophic vaginitis indication 52441000
Urethral atrophy indication 52620003
Primary ovarian failure indication 65846009
Acne vulgaris indication 88616000
Postmenopausal osteoporosis indication 102447009
Menopausal flushing indication 198436008
Atrophic vulva indication 248861000 DOID:14275
Advanced Prostatic Carcinoma indication
Metastatic Breast Carcinoma indication
Metastatic Prostate Carcinoma indication
Amenorrhea off-label use 14302001 DOID:13938
Polycystic ovaries off-label use 69878008
Dysmenorrhea off-label use 266599000
Postcoital contraception off-label use 268463003
Abnormal uterine bleeding unrelated to menstrual cycle off-label use 312984006
Menorrhagia off-label use 386692008
Pre-Menopausal Osteoporosis off-label use
Heart valve disorder contraindication 368009 DOID:4079
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Gynecomastia contraindication 4754008 DOID:12698
Hypocalcemia contraindication 5291005
Alcoholism contraindication 7200002
Weight gain finding contraindication 8943002
Hypercholesterolemia contraindication 13644009
Hyperkalemia contraindication 14140009
Jaundice contraindication 18165001
Toxic shock syndrome contraindication 18504008 DOID:14115
Myocardial infarction contraindication 22298006 DOID:5844
Fibroadenosis of breast contraindication 23260002 DOID:10352
Diplopia contraindication 24982008
Retinal hemorrhage contraindication 28998008
Depressive disorder contraindication 35489007
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Hyperlipidemia contraindication 55822004 DOID:1168
Heart disease contraindication 56265001 DOID:114
Anorexia nervosa contraindication 56882008 DOID:8689
Benign mammary dysplasia contraindication 57993004
Acute nephropathy contraindication 58574008
Obstructive hyperbilirubinemia contraindication 59848001
Hepatic failure contraindication 59927004
Cerebrovascular disease contraindication 62914000 DOID:6713
Thrombophlebitis contraindication 64156001 DOID:3875
Osteoporosis contraindication 64859006 DOID:11476
Intermenstrual bleeding - irregular contraindication 64996003
Hypercalcemia contraindication 66931009 DOID:12678
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Hyperglycemia contraindication 80394007 DOID:4195
Heart failure contraindication 84114007 DOID:6000
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Malignant neoplasm of liver contraindication 93870000 DOID:3571
Uterine fibroids contraindication 95315005 DOID:13223
Neoplasm of prostate contraindication 126906006 DOID:10283
Neoplasm of female genital organ contraindication 126907002 DOID:120
Deep venous thrombosis contraindication 128053003
Seizure disorder contraindication 128613002
Endometriosis contraindication 129103003
Bed-ridden contraindication 160685001
Liver function tests abnormal contraindication 166603001
Mammography abnormal contraindication 168750009
Angina pectoris contraindication 194828000
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Cholestasis of pregnancy contraindication 235888006
Metabolic syndrome X contraindication 237602007 DOID:14221
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Osteopenia contraindication 312894000
Functional visual loss contraindication 313165001
Non-Q wave myocardial infarction contraindication 314207007
Malignant tumor of cervix contraindication 363354003 DOID:4362
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Porphyria contraindication 418470004
Resistance to activated protein C due to Factor V Leiden contraindication 421527008
Optic disc edema contraindication 423341008 DOID:146
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Diabetes with Vascular Disease Complication contraindication
Breast Carcinoma in Males contraindication
Acute Thromboembolic Stroke contraindication
Major Surgery with Prolonged Post-Operative Immobilization contraindication
Nonspecific Abnormal Papanicolaou Smear of Cervix contraindication
Worsening Headache Disorder contraindication
Benign Hepatic Cell Adenoma contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.13 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MCG VAGIFEM NOVO NORDISK INC N020908 Nov. 25, 2009 RX TABLET VAGINAL 7018992 Sept. 17, 2022 TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL 9346822 Feb. 17, 2024 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN
0.025MG/24HR MINIVELLE NOVEN N203752 Sept. 23, 2014 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.0375MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.05MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.075MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.1MG/24HR MINIVELLE NOVEN N203752 Oct. 29, 2012 RX FILM, EXTENDED RELEASE TRANSDERMAL 9730900 July 10, 2028 A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10835487 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10835487 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11241445 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11241445 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11246875 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11246875 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10537581 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10835487 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10835487 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11241445 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11241445 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11246875 Nov. 21, 2032 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 11246875 Nov. 21, 2032 TREATMENT OF DYSPAREUNIA
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 10206932 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 10675288 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 11033626 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 8846648 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 8846649 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 8933059 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 9114145 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 9114146 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.5MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Dec. 28, 2021 RX CAPSULE ORAL 9301920 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 10206932 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 10675288 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 10806740 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 11033626 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 11103513 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 8846648 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 8846649 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9006222 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9114145 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9114146 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
1MG;100MG BIJUVA THERAPEUTICSMD INC N210132 Oct. 28, 2018 RX CAPSULE ORAL 9301920 Nov. 21, 2032 TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10668082 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10668082 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10888516 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10888516 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10471072 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10568891 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10668082 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10668082 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10888516 June 18, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10888516 June 18, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.004MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10258630 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 10398708 Dec. 20, 2033 TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY
0.01MG IMVEXXY THERAPEUTICSMD INC N208564 May 29, 2018 RX INSERT VAGINAL 9180091 Dec. 20, 2033 TREATMENT OF DYSPAREUNIA
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE ORIAHNN (COPACKAGED) ABBVIE INC N213388 May 29, 2020 RX CAPSULE ORAL 10881659 March 14, 2034 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE ORIAHNN (COPACKAGED) ABBVIE INC N213388 May 29, 2020 RX CAPSULE ORAL 11045470 March 14, 2034 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL 11033551 Sept. 29, 2037 MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE ORIAHNN (COPACKAGED) ABBVIE INC N213388 May 29, 2020 RX CAPSULE ORAL May 29, 2023 NEW PRODUCT
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE ORIAHNN (COPACKAGED) ABBVIE INC N213388 May 29, 2020 RX CAPSULE ORAL July 23, 2023 NEW CHEMICAL ENTITY
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL May 26, 2024 NEW PRODUCT
1MG;0.5MG;40MG MYFEMBREE MYOVANT SCIENCES N214846 May 26, 2021 RX TABLET ORAL Dec. 18, 2025 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor AGONIST EC50 10.30 WOMBAT-PK CHEMBL
Aldehyde oxidase Enzyme IC50 6.54 WOMBAT-PK
Glucocorticoid receptor Nuclear hormone receptor Ki 4.73 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 4.93 DRUG MATRIX
Androgen receptor Nuclear hormone receptor IC50 7.72 CHEMBL
Calcium-activated potassium channel subunit alpha-1 Ion channel ACTIVATOR EC50 5.60 IUPHAR
Estrogen receptor beta Nuclear hormone receptor EC50 9.70 WOMBAT-PK
G-protein coupled estrogen receptor 1 GPCR EC50 9.52 WOMBAT-PK
Corticosteroid-binding globulin Secreted Ki 5 CHEMBL
Steryl-sulfatase Enzyme IC50 4.08 CHEMBL
Sex hormone-binding globulin Secreted Kd 8.83 CHEMBL
Steroid hormone receptor ERR1 Nuclear hormone receptor IC50 8.44 CHEMBL
Steroid hormone receptor ERR2 Nuclear hormone receptor IC50 8.49 CHEMBL
Cytochrome P450 1B1 Enzyme Ki 5.72 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.24 DRUG MATRIX
Androgen receptor Transcription factor IC50 6.39 CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 4.95 DRUG MATRIX
Progesterone receptor Transcription factor Ki 5.37 DRUG MATRIX
Estrogen receptor Transcription factor IC50 8.72 CHEMBL
Estrogen receptor beta Transcription factor IC50 8.77 CHEMBL
Estrogen receptor beta Transcription factor IC50 8.64 CHEMBL
Estrogen receptor Transcription factor IC50 8.66 CHEMBL
Estrogen receptor Transcription factor IC50 9.45 CHEMBL

External reference:

IDSource
4021205 VUID
N0000148651 NUI
D00105 KEGG_DRUG
35380-71-3 SECONDARY_CAS_RN
4017609 VANDF
4021205 VANDF
C0014912 UMLSCUI
CHEBI:16469 CHEBI
EST PDB_CHEM_ID
CHEMBL135 ChEMBL_ID
DB00783 DRUGBANK_ID
D004958 MESH_DESCRIPTOR_UI
5757 PUBCHEM_CID
406 INN_ID
4TI98Z838E UNII
236859 RXNORM
160774 MMSL
18201 MMSL
36188 MMSL
4684 MMSL
6157 MMSL
73244 MMSL
8602 MMSL
d00537 MMSL
001265 NDDF
007018 NDDF
116070003 SNOMEDCT_US
126172005 SNOMEDCT_US
12839006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Estring HUMAN PRESCRIPTION DRUG LABEL 1 0013-2150 RING 2 mg VAGINAL NDA 27 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5885 PATCH 0.03 mg TRANSDERMAL NDA 35 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5886 PATCH 0.05 mg TRANSDERMAL NDA 35 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5887 PATCH 0.08 mg TRANSDERMAL NDA 35 sections
Alora HUMAN PRESCRIPTION DRUG LABEL 1 0023-5888 PATCH 0.10 mg TRANSDERMAL NDA 35 sections
ELESTRIN HUMAN PRESCRIPTION DRUG LABEL 1 0037-4801 GEL, METERED 0.52 mg TOPICAL NDA 33 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0343 PATCH, EXTENDED RELEASE 0.04 mg TRANSDERMAL NDA 33 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0344 PATCH, EXTENDED RELEASE 0.05 mg TRANSDERMAL NDA 33 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0345 PATCH, EXTENDED RELEASE 0.08 mg TRANSDERMAL NDA 33 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0346 PATCH, EXTENDED RELEASE 0.10 mg TRANSDERMAL NDA 33 sections
Vivelle-Dot HUMAN PRESCRIPTION DRUG LABEL 1 0078-0365 PATCH, EXTENDED RELEASE 0.03 mg TRANSDERMAL NDA 33 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0093-3223 INSERT 10 ug VAGINAL ANDA 29 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0093-3541 CREAM 0.10 mg VAGINAL ANDA 25 sections
Mimvey HUMAN PRESCRIPTION DRUG LABEL 2 0093-5455 TABLET, FILM COATED 1 mg ORAL ANDA 30 sections
Estradiol Vaginal HUMAN PRESCRIPTION DRUG LABEL 1 0115-1518 CREAM 0.10 mg VAGINAL ANDA 23 sections
Vagifem HUMAN PRESCRIPTION DRUG LABEL 1 0169-5176 INSERT 10 ug VAGINAL NDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3349 PATCH 0.03 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3350 PATCH 0.05 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3351 PATCH 0.08 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3352 PATCH 0.10 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3360 PATCH 0.04 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-3361 PATCH 0.06 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4619 PATCH 0.03 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4620 PATCH 0.04 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4621 PATCH 0.05 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4622 PATCH 0.08 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4623 PATCH 0.10 mg TRANSDERMAL ANDA 30 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4640 PATCH 0.10 mg TRANSDERMAL ANDA 31 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4641 PATCH 0.08 mg TRANSDERMAL ANDA 31 sections
Estradiol HUMAN PRESCRIPTION DRUG LABEL 1 0378-4642 PATCH 0.05 mg TRANSDERMAL ANDA 31 sections